Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement
Journal Articles American Journal of Clinical Dermatology Year : 2024

Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study

Marcus O Butler
  • Function : Author
  • PersonId : 1431484
Marie Beylot-Barry
  • Function : Author
  • PersonId : 1101824
Philippe Saiag
  • Function : Author
  • PersonId : 995135
Mahtab Samimi
Francesca Spada
  • Function : Author
  • PersonId : 1431485
Michel de Pontville
  • Function : Author
  • PersonId : 1431486
Michele Maio
  • Function : Author
  • PersonId : 1431487
Alfonso Berrocal
  • Function : Author
  • PersonId : 1431488
Debasmita Das
  • Function : Author
  • PersonId : 1431491
Dmitri Grebennik
  • Function : Author
  • PersonId : 1431492

Abstract

Background: The phase III KEYNOTE-913 study was conducted to evaluate the efficacy and safety of pembrolizumab as first-line therapy in patients with advanced Merkel cell carcinoma (MCC). Objective: The aim was to report results from the primary analysis of KEYNOTE-913. Patients and methods: Patients with recurrent locally advanced or metastatic MCC received pembrolizumab 200 mg intravenously every 3 weeks for up to 35 treatments (~ 2 years). The primary end point was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) by blinded independent central review (BICR). Secondary end points were duration of response (DOR) and progression-free survival (PFS) per RECIST v1.1 by BICR, overall survival (OS), and safety and tolerability. Results: Fifty-five patients were treated with pembrolizumab. The median time from first dose to data cutoff (February 15, 2024) was 50.3 months (range 38.7-59.4). The ORR was 49% (95% confidence interval [CI] 35-63), with 12 complete responses and 15 partial responses. The median DOR was 39.8 months (range 4.8-52.5+), and the 24-month DOR rate was 69%. The median PFS was 9.3 months (95% CI 3-26), and the 24-month PFS rate was 39%. The median OS was 24.3 months (95% CI 12.4 to not reached), and the 24-month OS rate was 51%. Any-grade treatment-related adverse events (AEs) occurred in 38 patients (69%); 13 patients (24%) experienced grade 3-5 AEs. The most common treatment-related AEs were fatigue (n = 12 [22%]), pruritus (n = 12 [22%]), and lipase increase (n = 10 [18%]). One patient died of treatment-related Guillain-Barré syndrome. Conclusions: Pembrolizumab provided durable antitumor activity and promising survival and had a manageable safety profile in patients with recurrent locally advanced or metastatic MCC, supporting its use in this population.
Fichier principal
Vignette du fichier
2024_Mortier_Am-J-Clin-Dermatol_early.pdf (709.07 Ko) Télécharger le fichier
Origin Files produced by the author(s)
Licence

Dates and versions

hal-04749918 , version 1 (23-10-2024)

Licence

Identifiers

Cite

Laurent Mortier, Lisa Villabona, Ben Lawrence, Ana Arance, Marcus O Butler, et al.. Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study. American Journal of Clinical Dermatology, 2024, 25 (6), pp.987-996. ⟨10.1007/s40257-024-00885-w⟩. ⟨hal-04749918⟩
0 View
0 Download

Altmetric

Share

More